<qa>  What is the primary objective of the oral thrombopoietin receptorThe primary objective is to assess the safety and efficacy of the oral thrombopoietin receptor agonist TPO-R agonist eltrombopag in moderate aplastic anemia patients or patients with bone marrow failure and unilineage cytopenia. Secondary objectives include the analysis of the incidence and severity of bleeding, clonal evolution to PNH, clonal chromosomal population in bone marrow, myelodysplasia by morphology, or acute leukemia and the impact on quality of life. 